Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 5 studies | 23% ± 7% | |
endothelial cell | 3 studies | 21% ± 3% | |
GABAergic neuron | 3 studies | 18% ± 2% | |
glutamatergic neuron | 3 studies | 26% ± 5% |
Insufficient scRNA-seq data for expression of CCAR2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 5244.45 | 258 / 258 | 100% | 36.38 | 230 / 230 |
esophagus | 100% | 4296.23 | 1445 / 1445 | 100% | 30.86 | 183 / 183 |
prostate | 100% | 5287.64 | 245 / 245 | 100% | 36.25 | 502 / 502 |
skin | 100% | 5570.73 | 1809 / 1809 | 100% | 53.99 | 472 / 472 |
uterus | 100% | 5142.99 | 170 / 170 | 100% | 47.22 | 459 / 459 |
thymus | 100% | 4767.43 | 653 / 653 | 100% | 43.20 | 604 / 605 |
brain | 100% | 4210.47 | 2637 / 2642 | 100% | 61.32 | 705 / 705 |
ovary | 100% | 5060.60 | 180 / 180 | 100% | 28.93 | 429 / 430 |
lung | 100% | 4565.98 | 578 / 578 | 100% | 33.32 | 1152 / 1155 |
pancreas | 100% | 2624.16 | 327 / 328 | 100% | 36.36 | 178 / 178 |
stomach | 100% | 3457.22 | 359 / 359 | 100% | 33.87 | 285 / 286 |
intestine | 100% | 4661.25 | 966 / 966 | 100% | 36.86 | 525 / 527 |
breast | 100% | 4834.06 | 459 / 459 | 100% | 42.36 | 1113 / 1118 |
bladder | 100% | 4658.90 | 21 / 21 | 99% | 39.23 | 501 / 504 |
kidney | 100% | 3990.00 | 89 / 89 | 99% | 29.93 | 895 / 901 |
liver | 100% | 2090.84 | 226 / 226 | 95% | 17.51 | 387 / 406 |
adipose | 100% | 4213.15 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 38.05 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 53.67 | 29 / 29 |
muscle | 100% | 3818.24 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 6933.75 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 50.08 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 16.21 | 1 / 1 |
blood vessel | 100% | 3622.53 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 100% | 2526.31 | 858 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 96% | 2978.20 | 894 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0032435 | Biological process | negative regulation of proteasomal ubiquitin-dependent protein catabolic process |
GO_0006397 | Biological process | mRNA processing |
GO_0090263 | Biological process | positive regulation of canonical Wnt signaling pathway |
GO_0006974 | Biological process | DNA damage response |
GO_0009411 | Biological process | response to UV |
GO_0032784 | Biological process | regulation of DNA-templated transcription elongation |
GO_0042752 | Biological process | regulation of circadian rhythm |
GO_0043086 | Biological process | negative regulation of catalytic activity |
GO_0031647 | Biological process | regulation of protein stability |
GO_0043653 | Biological process | mitochondrial fragmentation involved in apoptotic process |
GO_0090311 | Biological process | regulation of protein deacetylation |
GO_2000003 | Biological process | positive regulation of DNA damage checkpoint |
GO_0008380 | Biological process | RNA splicing |
GO_1902230 | Biological process | negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage |
GO_0016055 | Biological process | Wnt signaling pathway |
GO_0043065 | Biological process | positive regulation of apoptotic process |
GO_0048511 | Biological process | rhythmic process |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0030308 | Biological process | negative regulation of cell growth |
GO_0044609 | Cellular component | DBIRD complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005759 | Cellular component | mitochondrial matrix |
GO_0005737 | Cellular component | cytoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0005819 | Cellular component | spindle |
GO_0005634 | Cellular component | nucleus |
GO_0019899 | Molecular function | enzyme binding |
GO_0004857 | Molecular function | enzyme inhibitor activity |
GO_0000774 | Molecular function | adenyl-nucleotide exchange factor activity |
GO_0051082 | Molecular function | unfolded protein binding |
GO_0000993 | Molecular function | RNA polymerase II complex binding |
GO_0003723 | Molecular function | RNA binding |
GO_0005515 | Molecular function | protein binding |
Gene name | CCAR2 |
Protein name | Cell cycle and apoptosis regulator 2 (KIAA1967, isoform CRA_b) Cell cycle and apoptosis regulator protein 2 (Cell division cycle and apoptosis regulator protein 2) (DBIRD complex subunit KIAA1967) (Deleted in breast cancer gene 1 protein) (DBC-1) (DBC.1) (NET35) (p30 DBC) Cell cycle and apoptosis regulator 2 |
Synonyms | KIAA1967 DBC1 hCG_2043023 |
Description | FUNCTION: Core component of the DBIRD complex, a multiprotein complex that acts at the interface between core mRNP particles and RNA polymerase II (RNAPII) and integrates transcript elongation with the regulation of alternative splicing: the DBIRD complex affects local transcript elongation rates and alternative splicing of a large set of exons embedded in (A + T)-rich DNA regions . Inhibits SIRT1 deacetylase activity leading to increasing levels of p53/TP53 acetylation and p53-mediated apoptosis . Inhibits SUV39H1 methyltransferase activity . Mediates ligand-dependent transcriptional activation by nuclear hormone receptors . Plays a critical role in maintaining genomic stability and cellular integrity following UV-induced genotoxic stress . Regulates the circadian expression of the core clock components NR1D1 and BMAL1 . Enhances the transcriptional repressor activity of NR1D1 through stabilization of NR1D1 protein levels by preventing its ubiquitination and subsequent degradation . Represses the ligand-dependent transcriptional activation function of ESR2 . Acts as a regulator of PCK1 expression and gluconeogenesis by a mechanism that involves, at least in part, both NR1D1 and SIRT1 . Negatively regulates the deacetylase activity of HDAC3 and can alter its subcellular localization . Positively regulates the beta-catenin pathway (canonical Wnt signaling pathway) and is required for MCC-mediated repression of the beta-catenin pathway . Represses ligand-dependent transcriptional activation function of NR1H2 and NR1H3 and inhibits the interaction of SIRT1 with NR1H3 . Plays an important role in tumor suppression through p53/TP53 regulation; stabilizes p53/TP53 by affecting its interaction with ubiquitin ligase MDM2 . Represses the transcriptional activator activity of BRCA1 . Inhibits SIRT1 in a CHEK2 and PSEM3-dependent manner and inhibits the activity of CHEK2 in vitro . . |
Accessions | E5RFJ3 ENST00000521837.5 H0YB24 ENST00000308511.9 [Q8N163-1] ENST00000521301.5 E5RHH8 ENST00000520861.5 ENST00000520738.5 ENST00000389279.7 [Q8N163-1] E5RHJ4 H0YC58 H0YC69 ENST00000522599.5 E5RGU7 Q8N163 G3V119 ENST00000523349.5 ENST00000518989.1 ENST00000523801.5 |